Business
Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine
Agreement to help advance lead clinical sensitizer drug candidate ROCKVILLE, Md., Sept. 20, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc.
About this update from Shuttle Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Agreement to help advance lead clinical sensitizer drug candidate\nROCKVILLE, Md., Sept. 20, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its side effects, entered into an agreement with TCG GreenChem, Inc. to manufacture Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, for use in formulating the drug product for testing in clinical trials of Ropidoxuridine and RT of cancers.\n\n \n \n \n \n \n \n\n \n\"Shuttle Pharma's platform of sensitizers offers a pipeline of product candidates designed to address the urgent clinical need and the current limitations of using 'off-label' drugs with potential new sensitizer agents,\" said Dr. Anatoly Dritschilo, Chief Executive Officer of Shuttle Pharmaceuticals. \"Ropidoxuridine, our lead clinical sensitizer drug candidate, sensitizes rapidly growing cancer cells and selective histone deacetylase (HDAC) inhibitors, to sensitize cancer cells and stimulate the immune system. Our novel technologies will be tested in combination with radiation therapies, such as conventional X-ray and proton radiation therapies, and in combination with immune therapies.\"\n\"Today's agreement with TCG GreenChem allows us to advance our clinical research, including our proposed Phase II clinical trials, to establish the data necessary for the FDA to determine efficacy in treating brain tumors, sarcomas and pancreatic cancers, diseases that offer potential for orphan designations. For instance, the FDA has already granted approval of our application for orphan-drug designation for Ropidoxuridine for the treatment of glioblastoma. We look forward to working with TCG GreenChem to advance our clinical work to improve outcomes for these cancer patients,\" Dr. Dritschilo concluded.\nIn conjunction with manufacturing Ropidoxuridine, TCG GreenChem will perform process research, development and optimization work for Shuttle Pharma related to Ropidoxuridine and create working standards of starting materials and intermediates to support the qualitative/quantitative analysis of the drug reaction progress, determination of impurities, total mass balance and assay yields of the reactions. Shuttle Pharma wil...